Results 181 to 190 of about 472,131 (258)

Mechanistic insights and molecular therapy for neuroendocrine prostate cancer. [PDF]

Front Oncol
Niu Y, Zhang S, Zhang S, Tao J, Zhu Y.
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer. [PDF]

Cancers (Basel)
Guida C, Evangelista L, Spadafora M, Facchini G, Mansi L.   +4 more
europepmc   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Prostate Cancer, Genetic Susceptibility, and Risk of Chronic Non-Urological Complications. [PDF]

Prostate
Helfand BT, Shi Z, Mulford AJ, Tran H, Wei J, Ashworth A, Zheng SL, Sanders AR, Graham N, Cabral J, Lu J, Beebe-Dimmer JL, Cooney KA, Duggan D, Xu J.   +14 more
europepmc   +1 more source

Bariatric surgery and prostate cancer screening: insights into preventive men's health. [PDF]

Ann Med Surg (Lond)
Mugisha AI.
europepmc   +1 more source

Pt‐TiO2 mesoporous nanosystem co‐delivering phlorezin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation

BMEMat, EarlyView.
Abstract Hepatocellular carcinoma (HCC), ranking as the third leading cause of cancer‐related mortality globally, continues to pose significant therapeutic challenges. Here, we developed an innovative nanosystem, Phl@PT, based on Pt‐TiO2 nanoparticles for the co‐delivery of Phlorezin, presenting a novel approach for HCC treatment through sonodynamic ...
Kairui Liu, Bo Zhang, Yue Wan, Zhiru Yang, Abdusami Abdurahman, Mengxin He, Shengtao Hu, Yi Zhang, Xiaoke Li, Jin Chang, Jun Kang, Liren Liu, Wanghua Liu, Shao Li   +13 more
wiley   +1 more source

Hypofractionated radiotherapy for prostate cancer: a bibliometric analysis. [PDF]

Discov Oncol
Meng L, Di Y, Wang Y, Qu B.
europepmc   +1 more source